Reduced Lysosomal Acid Lipase Activity in Adult Patients With Non-alcoholic Fatty Liver Disease

EBioMedicine

Volumn 2, Issue 7, 2015, Pages 750-754

  Baratta, Francesco ^a   Pastori, Daniele ^a   Del Ben, Maria ^a   Polimeni, Licia ^a   Labbadia, Giancarlo ^a   Di Santo, Serena ^a   Piemonte, Fiorella ^b   Tozzi, Giulia ^b   Violi, Francesco ^a   Angelico, Francesco ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

Author keywords

Lysosomal acid lipase; Metabolic syndrome; Non alcoholic fatty liver disease; Non alcoholic steatohepatitis; Statins

Indexed keywords

ACID LIPASE; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CREATININE; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LYSOSOMAL ACID LIPASE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; CHOLESTEROL ESTERASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; ARTICLE; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE ASSOCIATION; ECHOGRAPHY; ENZYME ACTIVITY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INSULIN RESISTANCE; LIPID METABOLISM; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; CASE CONTROL STUDY; ENZYMOLOGY; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; NON-ALCOHOLIC FATTY LIVER DISEASE; STATISTICAL MODEL;

ADULT; CASE-CONTROL STUDIES; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NON-ALCOHOLIC FATTY LIVER DISEASE; STEROL ESTERASE;

EID: 84951573365     PISSN: None     EISSN: 23523964     Source Type: Journal    
DOI: 10.1016/j.ebiom.2015.05.018     Document Type: Article

References (36)

1. Angelico F., Del Ben M., Conti R., et al. Insulin resistance, the metabolic syndrome, and nonalcoholic fatty liver disease. J. Clin. Endocrinol. Metab. 2005, 90(3):1578-1582.
2. Angelico F., Burattin M., Alessandri C., Del Ben M., Lirussi F. Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis. Cochrane Database Syst. Rev. 2007, 1. (CD005166).
3. Anon. Expert panel on detection E, treatment of high blood cholesterol in A. Executive summary of the third report of The National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). Jama 2001, 285(19):2486-2497.
4. Authors, Task Force M., Ryden L., Grant P.J., et al. ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the task force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur. Heart J. 2013, 34(39):3035-3087.
5. Bellentani S., Saccoccio G., Masutti F., et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann. Intern. Med. 2000, 132(2):112-117.
6. Bernstein D.L., Hulkova H., Bialer M.G., Desnick R.J. Cholesteryl ester storage disease: review of the findings in 135 reported patients with an underdiagnosed disease. J. Hepatol. 2013, 58(6):1230-1243.
7. Chalasani N., Younossi Z., Lavine J.E., et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012, 55(6):2005-2023.
8. Compare D., Coccoli P., Rocco A., et al. Gut-liver axis: the impact of gut microbiota on non alcoholic fatty liver disease. Nutr. Metab. Cardiovasc. Dis. NMCD 2012, 22(6):471-476.
9. Corey K.E., Vuppalanchi R., Vos M., et al. Improvement in liver histology is associated with reduction in dyslipidemia in children with nonalcoholic fatty liver disease. J. Pediatr. Gastroenterol. Nutr. 2015, 60(3):360-367.
10. Del Ben M., Polimeni L., Carnevale R., et al. NOX2-generated oxidative stress is associated with severity of ultrasound liver steatosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol. 2014, 14(1):81.
11. Del Ben M., Polimeni L., Brancorsini M., et al. Non-alcoholic fatty liver disease, metabolic syndrome and patatin-like phospholipase domain-containing protein3 gene variants. Eur. J. Intern. Med. 2014, 25(6):566-570.
12. Del Ben M., Polimeni L., Baratta F., Pastori D., Loffredo L., Angelico F. Modern approach to the clinical management of non-alcoholic fatty liver disease. World J. Gastroenterol. WJG 2014, 20(26):8341-8350.
13. Dubland J.A., Francis G.A. Lysosomal acid lipase: at the crossroads of normal and atherogenic cholesterol metabolism. Front. Cell Dev. Biol. 2015, 3:3.
14. Farrell G.C., Larter C.Z. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006, 43(2 Suppl 1):S99-S112.
15. Fasano T., Pisciotta L., Bocchi L., et al. Lysosomal lipase deficiency: molecular characterization of eleven patients with Wolman or cholesteryl ester storage disease. Mol. Genet. Metab. 2012, 105(3):450-456.
16. Fouchier S.W., Defesche J.C. Lysosomal acid lipase A and the hypercholesterolaemic phenotype. Curr. Opin. Lipidol. 2013, 24(4):332-338.
17. Hamaguchi M., Kojima T., Itoh Y., et al. The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation. Am. J. Gastroenterol. 2007, 102(12):2708-2715.
18. Hamilton J., Jones I., Srivastava R., Galloway P. A new method for the measurement of lysosomal acid lipase in dried blood spots using the inhibitor Lalistat 2. Clin. Chim. Acta Int. J. Clin. Chem. 2012, 413(15-16):1207-1210.
19. Kemmer N., Neff G.W., Franco E., et al. Nonalcoholic fatty liver disease epidemic and its implications for liver transplantation. Transplantation 2013, 96(10):860-862.
20. Mancia G., Fagard R., Narkiewicz K., et al. 2013 practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC task force for the management of arterial hypertension. J. Hypertens. 2013, 31(10):1925-1938.
21. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28(7):412-419.
22. Muntoni S., Wiebusch H., Jansen-Rust M., et al. Heterozygosity for lysosomal acid lipase E8SJM mutation and serum lipid concentrations. Nutr. Metab. Cardiovasc. Dis. NMCD 2013, 23(8):732-736.
23. Pastori D., Polimeni L., Baratta F., Pani A., Del Ben M., Angelico F. The efficacy and safety of statins for the treatment of non-alcoholic fatty liver disease. Dig. liver Dis.: Off. J. Ital. Soc. Gastroenterol. Ital. Assoc. Stud. Liver 2015, 47(1):4-11.
24. Pastori D., Loffredo L., Perri L., et al. Relation of nonalcoholic fatty liver disease and Framingham risk score to flow-mediated dilation in patients with cardiometabolic risk factors. Am. J. Cardiol. 2015, 115(10):1402-1406.
25. Pisciotta L., Fresa R., Bellocchio A., et al. Cholesteryl ester storage disease (CESD) due to novel mutations in the LIPA gene. Mol. Genet. Metab. 2009, 97(2):143-148.
26. Puri P., Baillie R.A., Wiest M.M., et al. A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology 2007, 46(4):1081-1090.
27. Reiner Z., Guardamagna O., Nair D., et al. Lysosomal acid lipase deficiency-an under-recognized cause of dyslipidaemia and liver dysfunction. Atherosclerosis 2014, 235(1):21-30.
28. Reynolds T. Cholesteryl ester storage disease: a rare and possibly treatable cause of premature vascular disease and cirrhosis. J. Clin. Pathol. 2013, 66(11):918-923.
29. Sanyal A.J., Brunt E.M., Kleiner D.E., et al. Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology 2011, 54(1):344-353.
30. Sanyal A.J., Friedman S.L., McCullough A.J., Dimick L. Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: Findings and recommendations from an american association for the study of liver diseases (aasld)-food and drug administration (fda) joint workshop. Hepatology Apr 2015, 61(4):1392-1405. 10.1002/hep.27678.
31. Saverymuttu S.H., Joseph A.E., Maxwell J.D. Ultrasound scanning in the detection of hepatic fibrosis and steatosis. Br. Med. J. 1986, 292(6512):13-15.
32. Singh R., Kaushik S., Wang Y., et al. Autophagy regulates lipid metabolism. Nature 2009, 458(7242):1131-1135.
33. Sookoian S., Pirola C.J. Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: a systematic review. J. Hepatol. 2008, 49(4):600-607.
34. Thelwall P.E., Smith F.E., Leavitt M.C., et al. Hepatic cholesteryl ester accumulation in lysosomal acid lipase deficiency: non-invasive identification and treatment monitoring by magnetic resonance. J. Hepatol. 2013, 59(3):543-549.
35. Valayannopoulos V., Malinova V., Honzik T., et al. Sebelipase alfa over 52weeks reduces serum transaminases, liver volume and improves serum lipids in patients with lysosomal acid lipase deficiency. J. Hepatol. 2014, 61(5):1135-1142.
36. Vernon G., Baranova A., Younossi Z.M. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment. Pharmacol. Ther. 2011, 34(3):274-285.